This is important as ICI combination therapies such as anti-PD-1/anti-CTLA-4, while it leads to prolonged survival in melanoma patients [1], are often accompanied by severe immunogenic adverse events, mostly to the GI tract, skin, liver, lungs, that can interrupt or even suspend the therapy, if not manageable [43]. Here, CTLA4 is linked to melanoma.